Phaseline

Companies › MedTrace Pharma

MedTrace Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[O-15]-Water PET Myocardial Perfusion Imaging ([15-O]-H2O injection)
PET imaging agent labeled with radioisotope [15-O] for myocardial perfusion imaging
–Phase 3Coronary Artery Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05134012[O-15]-Water PET Myocardial Perfusion Imaging ([15-O]-H2O injection)Phase 3Coronary Artery DiseaseCardiovascularOct 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

CeleCor Therapeutics SPH Qingdao Growful Pharmacetical Hanlim Pharm. Trust Bio-sonics Liquidia Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.